Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 6, 2009, Pages 1784-1789

  Kasagami, Takeo ^a   Kim, In Hae ^a   Tsai, Hsing Ju ^a   Nishi, Kosuke ^a   Hammock, Bruce D ^a   Morisseau, Christophe ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti inflammation; Hypertension; Intramolecular hydrogen bond; Metabolic and chemical stability; Salicylate; Soluble epoxide hydrolase; Urea

Indexed keywords

ENZYME INHIBITOR; EPOXIDE HYDROLASE; N ADAMANTYL N' PHENYL UREA DERIVATIVE; SALICYLIC ACID DERIVATIVE; SALICYLIC ACID METHYL ESTER; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; NONHUMAN; PHARMACOPHORE;

ANTI-INFLAMMATORY AGENTS; BENZOIC ACIDS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; EPOXIDE HYDROLASES; HUMANS; HYDROGEN BONDING; HYDROLYSIS; HYPERTENSION; INHIBITORY CONCENTRATION 50; KINETICS; MODELS, CHEMICAL; SALICYLATES; SPECTROMETRY, FLUORESCENCE; UREA;

EID: 61349106718     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.01.069     Document Type: Article

References (32)

1. Morisseau C., and Hammock B.D. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 311
2. Harder D.R., Campbell W.B., and Roman R.J. J. Vasc. Res. 32 (1995) 79
3. Campbell W.B., Gebremedhin D., Pratt P.F., and Harder D.R. Circ. Res. 78 (1996) 415
4. Node K., Huo Y., Ruan X., Yang B., Spiecker M., Ley K., Zeldin D.C., and Liao J.K. Science 285 (1999) 1276
5. Newman J.W., Morisseau C., and Hammock B.D. Prog. Lipid Res. 44 (2005) 1
6. Spiecker M., and Liao J.K. Arch. Biochem. Biophys. 433 (2005) 413
7. Schmelzer K.R., Kubala L., Newman J.W., Kim I.-H., Eiserich J.P., and Hammock B.D. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 9772
8. Schmelzer K.R., Inceoglu B., Kubala L., Kim I.-H., Links S.L., Eiserich J.P., and Hammock B.D. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 13646
9. Morisseau C., Goodrow M.H., Dowdy D., Zheng J., Greene J.F., Sanborn J.R., and Hammock B.D. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 8849
10. Nakagawa Y., Wheelock C.E., Morisseau C., Goodrow M.H., Hammock B.G., and Hammock B.D. Bioorg. Med. Chem. 8 (2000) 2663
11. Morisseau C., Newman J.W., Dowdy D.L., Goodrow M.H., and Hammock B.D. Chem. Res. Toxicol. 14 (2001) 409
12. Morisseau C., Goodrow M.H., Newman J.W., Wheelock C.E., Dowdy D.L., and Hammock B.D. Biochem. Pharmacol. 63 (2002) 1599
13. Morisseau C., Newman J.W., Tsai H.-J., Baecker P.A., and Hammock B.D. Bioorg. Med. Chem. Lett. 16 (2006) 5439
14. Kim I.-H., Morisseau C., Watanabe T., and Hammock B.D. J. Med. Chem. 47 (2004) 2110
15. Kim I.-H., Heirtzler F.R., Morisseau C., Nishi K., Tsai H.J., and Hammock B.D. J. Med. Chem. 48 (2005) 3621
16. Jones P.D., Tsai H.-J., Do Z.N., Morisseau C., and Hammock B.D. Bioorg. Med. Chem. Lett. 16 (2006) 5216
17. Kim I.-H., Nishi K., Tsai H.-J., Bradford T., Koda Y., Watanabe T., Morisseau C., Blanchfield J., Toth I., and Hammock B.D. Bioorg. Med. Chem. 15 (2007) 312
18. Hwang S.H., Tsai H.-J., Liu J.-Y., Morisseau C., and Hammock B.D. J. Med. Chem. 50 (2007) 3825
19. Kim I.-H., Tsai H.-J., Nishi K., Kasagami T., Morisseau C., and Hammock B.D. J. Med. Chem. 50 (2007) 5217
20. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Adv. Drug Delivery Rev. 46 (2001) 3
21. Gomez G.A., Morisseau C., Hammock B.D., and Christianson D.W. Protein Sci. 15 (2006) 58
22. Watanabe T., Morisseau C., Newman J.W., and Hammock B.D. Drug Metab. Dispos. 31 (2003) 846
23. Imai T., Taketani M., Shii M., Hosokawa M., and Chiba K. Drug Metab. Dispos. 34 (2006) 1734
24. Khan M.N., Fatope I.L., Isaac K.I., and Zubair M.O. J. Chem. Soc., Perkin Trans. 2 5 (1986) 655
25. Dennis A.S., van de Waterbeemd H., and Walker D.K. In: Mannhold R., Kubinyi H., and Timmerman H. (Eds). Pharmacokinetics and Metabolism in Drug Design Vol. 31 (2006), Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim 1-15
26. Jung O., Brandes R.P., Kim I.-H., Schweda F., Schmidt R., Hammock B.D., Busse R., and Fleming I. Hypertension 45 (2005) 759
27. Dorrance A.M., Rupp N., Pollock D.M., Newman J.W., Hammock B.D., and Imig J.D. J. Cardiovasc. Pharmacol. 46 (2005) 842
28. Imig J.D., Zhao X., Zaharis C.Z., Olearczyk J.J., Pollock D.M., Newman J.W., Kim I.-H., Watanabe T., and Hammock B.D. Hypertension 46 (2005) 975
29. Olearczyk J.J., Field M.B., Kim I.-H., Morisseau C., Hammock B.D., and Imig J.D. J. Pharmacol. Exp. Ther. 318 (2006) 1307
30. Huang H., Morisseau C., Wang J., Yang T., Falck J.R., Hammock B.D., and Wang M.H. Am. J. Physiol. Renal Physiol. 293 (2007) F342
31. Jones P.D., Wolf N.M., Morisseau C., Whetstone P., Hock B., and Hammock B.D. Anal. Biochem. 343 (2005) 66
32. Morisseau C., and Hammock B.D. In: Bus J.S., Costa L.G., Hodgson E., Lawrence D.A., and Reed D.J. (Eds). Techniques for Analysis of Chemical Biotransformation, Current Protocols in Toxicology (2007), John Wiley & Sons, New Jersey 4.23.1-4.23.18